Category: Pα+ - Psychedelic Alpha

Explore our new Pα+ Psychedelic Bill Tracker.

Read more about the article Pα+ Psychedelic Bulletin #218: FDA’s Farchione Says Psychedelic INDs Are “a Third” of Her Workload; Ipsos/Psychedelic Alpha Poll; Reunion Eyes Single Phase 3 in PPD; America’s 10 Million Microdosers

Pα+ Psychedelic Bulletin #218: FDA’s Farchione Says Psychedelic INDs Are “a Third” of Her Workload; Ipsos/Psychedelic Alpha Poll; Reunion Eyes Single Phase 3 in PPD; America’s 10 Million Microdosers

Post published:January 22, 2026
Post category:Psychedelic Bulletin Pα+

Read more about the article Psychedelic Funding, Public Markets, and M&A in 2025

Psychedelic Funding, Public Markets, and M&A in 2025

Post published:January 20, 2026
Post category:Analysis Pα+

Read more about the article Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Post published:January 15, 2026
Post category:2025 Year in Review Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin Becomes Helus

Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin Becomes Helus

Post published:January 8, 2026
Post category:Psychedelic Bulletin Pα+

Read more about the article 2025 Year in Review: Future(s) & Open Questions (Video)

2025 Year in Review: Future(s) & Open Questions (Video)

Post published:January 6, 2026
Post category:2025 Year in Review Analysis News Pα+

Read more about the article 2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video)

2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video)

Post published:December 30, 2025
Post category:2025 Year in Review Analysis News Pα+

Read more about the article 2025 Year in Review: Psychedelics in 2025 (Video)

2025 Year in Review: Psychedelics in 2025 (Video)

Post published:December 23, 2025
Post category:2025 Year in Review Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #216: Australia’s Psychedelics-for-Veterans Funding; New Mexico Targets 2026 Medical Psilocybin Launch; Radial Scores $50M; Otsuka’s “Novel Serotonergic Agonists”; Psilocybin Accelerates Brain Tumour Growth in Mice; Texas’ $50M Ibogaine Study Consortium

Pα+ Psychedelic Bulletin #216: Australia’s Psychedelics-for-Veterans Funding; New Mexico Targets 2026 Medical Psilocybin Launch; Radial Scores $50M; Otsuka’s “Novel Serotonergic Agonists”; Psilocybin Accelerates Brain Tumour Growth in Mice; Texas’ $50M Ibogaine Study Consortium

Post published:December 17, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

Post published:December 10, 2025
Post category:Interviews Pα+

Read more about the article Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to Heal Act Looks to Unlock Right to Try Psychedelics; Compass Clarifies Q1 Readout Plans

Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to Heal Act Looks to Unlock Right to Try Psychedelics; Compass Clarifies Q1 Readout Plans

Post published:December 5, 2025
Post category:Psychedelic Bulletin Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.